Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222499 | 0.86 | KDM1A (0.45) | KDM1AADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL2793318 | 0.83 | ADRA2A (0.39) | KDM1AADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL28465895 | 0.80 | KDM1A (0.48) | KDM1AADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL6760141 | 0.77 | KDM1A (0.41) | KDM1AHTR2CHTR2AHTR2BAR | |
| SCHEMBL6760145 | 0.77 | KDM1A (0.41) | KDM1AHTR2CHTR2AHTR2BAR | |
| SCHEMBL22145508 | 0.76 | KDM1A (0.46) | KDM1AADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL20232227 | 0.75 | KDM1A (0.44) | KDM1AADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL6761606 | 0.74 | CYP2C19 (0.39) | KDM1AAR | |
| SCHEMBL25438091 | 0.74 | KDM1A (0.43) | KDM1AADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL17779079 | 0.73 | CFTR (0.51) | HTR2CHTR2AHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2149560-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | KDM1A 3130/4885ADRA2A 454/4885HTR2C 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.